Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Concurrent With Radiotherapy in Muscle-Invasive Bladder Cancer
2024-514604-14-00Phase 2Authorised
- Sponsor
- SOGUG
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma of the bladder (TCC), sponsored by SOGUG. Primary endpoint: Pathological complete response. Planned start Jun 2024; status: authorised.
02
Drugs
atezolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2024-514604-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514604-14-00.